NanoMed Targeting Systems Inc. (NanoMed) is developing a market disruptive drug delivery system using magnetic targeting technology to revolutionize the drug delivery.
Our first application is a new treatment for atrial fibrillation - the most common cardiac arrhythmia disease, affecting over 2.6 million Americans, with more than 160,000 new cases each year. It is caused by abnormal nerve activity in the heart and characterized by a very fast, chaotic rhythm in the atria. In the U.S., AF causes more than 70,000 strokes each year. As the population ages, the prevalence of atrial fibrillation is expected to grow significantly, impacting up to 13 million in the US by 2050. The current leading procedure - RF ablation - is limited success rate (~50%), it is risky, long and costly. Also, since only electrophysiologists can perform it, there will not be enough physician to perform all needed procedures.
NTS procedure is safer, shorter, less costly and can be performed by any cardiologist.